Profitable pills: where to find the best biotech stocks

Marek Poszepczynski of the International Biotechnology Trust highlights three top biotech stocks to buy now.

A professional investor tells us where he'd put his money. This week: Marek Poszepczynski of the International Biotechnology Trust highlights three top biotech stocks.

Biotechnology is rightly classified as a growth sector, but not all companies have the same earnings potential. The drugs addressing the highest unmet medical needs tend to produce significant profits and consistent cash flows. Products that either cure a previously untreatable disease or improve patients' quality of life will sell well and are more likely to benefit from reimbursements by governments and health insurers.

Ideally, the product should be able to maintain a dominant position in its therapeutic area for a long period of time. A company is better able to protect its drug pricing and profitability if it faces fewer competitors. We have selected three stocks to fit these criteria, each with a different risk profile to cater for a variety of risk appetites.

Help for HIV and hepatitis patients

Gilead (Nasdaq: GILD)

But while the overall outlook for Gilead is robust, investors should be aware that the growth potential for this company is slowing as it is hard for such a large firm to expand rapidly. Investors with a higher risk appetite could look to smaller, faster-growing firms such as Vertex or Insmed.

The gold-standard cystic fibrosis drug

Vertex (Nasdaq: VRTX)

As this disease only affects a relatively small number of patients, the company has received orphan-drug status (this is granted to treatments for rare diseases). This allows Vertex to charge a high price for its product and the portfolio is also shielded from competition by Vertex's intellectual-property rights.

A crucial antibiotic

Insmed

(Nasdaq: INSM)

Investing in the antibiotic space has been tough in recent years despite the clear and growing unmet need. However, Insmed has succeeded in developing and launching Arikayce. Initial sales look robust.

Recommended

Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
19 Feb 2021
Our trade of the decade came good – what’s next?
Investment strategy

Our trade of the decade came good – what’s next?

Back in 2010 we said you should invest in unloved and undervalued Japanese stocks. If you had done that, you’d have made a nice return. So what should…
25 Feb 2021
Invest in water and provide a buffer against future pandemics
Soft commodities

Invest in water and provide a buffer against future pandemics

Global water shortages have long hampered growth and development, and climate change has exacerbated the problem. Will the coronavirus pandemic be a t…
25 Feb 2021
Mpac Group: making steady profits from premium packaging
Share tips

Mpac Group: making steady profits from premium packaging

Mpac Group’s automated packaging machines are sold to blue-chip clients in more than 80 countries worldwide. Dr Mike Tubbs looks at the company's pot…
24 Feb 2021

Most Popular

The days when you could get 7% from your bank are long gone – so what do you do?
Bitcoin

The days when you could get 7% from your bank are long gone – so what do you do?

With interest rates at rock bottom for so long, we’ve been forced to move from saving to speculating to earn any sort of return. Dominic Frisby asks w…
24 Feb 2021
Why you should still put money into a cash Isa
Cash ISAs

Why you should still put money into a cash Isa

Interest rates may be lousy, but tax-free saving into a cash Isa is still a good idea.
23 Feb 2021
Are we heading for another bond market tantrum?
Government bonds

Are we heading for another bond market tantrum?

The last time the US central bank tried tightening the purse strings, the bond markets threw a tantrum. With yields now rising, could we be about to s…
25 Feb 2021